Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

This was the stock's fourth consecutive day of losses.

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

The stock's rise snapped a five-day losing streak.

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...